Monopar presents new data, analyses from Phase 2 ALXN1840-WD-204 study

Monopar Therapeutics (MNPR) is presenting new data and analyses from the Phase 2 ALXN1840-WD-204 copper balance study at the American Association for the Study of Liver Diseases, AASLD, – The Liver Meeting 2025, taking place in Washington, D.C., from November 7-11, 2025. The mean daily copper balance among patients treated with ALXN1840 in the study was significantly lower – indicating improvement – compared with their pre-treatment baseline. Copper balance improved both during the initial 15 mg once-daily dosing period and over the entire treatment duration, which included patients receiving either 15 mg every other day or 30 mg once daily. Additional new nonclinical and clinical data supporting these findings from the ALXN1840-WD-204 study will also be presented.